Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome

Atsuyuki Watanabe, Kengo Fukushima Kusano, Hiroshi Morita, Daiji Miura, Wakako Sumida, Shigeki Hiramatsu, Kimikazu Banba, Nobuhiro Nishii, Satoshi Nagase, Kazufumi Nakamura, Satoru Sakuragi, Tohru Ohe

Research output: Contribution to journalArticlepeer-review

79 Citations (Scopus)


Aims: Arrhythmic storm or repetitive ventricular arrhythmia (VA) has been occasionally observed in Brugada syndrome (BS). A beta-adrenergic stimulator [isoproterenol (ISP)] has been reported to suppress this arrhythmic storm in sporadic cases. Accordingly, we investigated the antiarrhythmic effects of ISP infusion in consecutive BS patients with arrhythmic storm or repetitive VA. Methods and results: Seven BS patients with arrhythmic storm were studied. Intravenous ISP was administered as a bolus injection (1-2 μg), followed by continuous infusion (0.15 μg/min). Arrhythmic storm or repetitive VA was suppressed immediately after the bolus administration of ISP, which was followed by continuous infusion of low-dose ISP for 1-3 days. In all patients, ST-elevation decreased in right precordial leads. In six of the seven patients, VA subsided after the discontinuance of ISP. RR interval was shortened and ST-elevation in right precordial leads was decreased after ISP bolus injection. ST-elevation in right precordial leads remained decreased during continuous ISP infusion, whereas the RR interval returned to the control level. Conclusion: Continuous administration of low-dose ISP may be effective for the suppression of repetitive VA occurrence in patients with BS.

Original languageEnglish
Pages (from-to)1579-1583
Number of pages5
JournalEuropean Heart Journal
Issue number13
Publication statusPublished - Jul 2006


  • Brugada syndrome
  • Isoproterenol
  • Ventricular arrhythmia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome'. Together they form a unique fingerprint.

Cite this